Evolus (NASDAQ: EOLS) grants RSUs, PSUs and options to executive David Moatazedi
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
MOATAZEDI DAVID reported acquisition or exercise transactions in this Form 4 filing.
Evolus, Inc. director and officer David Moatazedi reported equity awards on February 17, 2026. He was granted 626,424 performance-based restricted stock units, where each unit can deliver up to 200% of a target share amount based on financial metrics and relative total shareholder return over a three-year period ending December 31, 2028. He also received 313,212 time-based restricted stock units and 457,541 stock options, each vesting in four equal annual installments starting on February 17, 2026, subject to continued service and potential acceleration in certain circumstances.
Positive
- None.
Negative
- None.
Insider Trade Summary
3 transactions reported
Mixed
3 txns
Insider
MOATAZEDI DAVID
Role
See Remarks
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Performance Restricted Stock Units | 626,424 | $0.00 | -- |
| Grant/Award | Stock Option (Right to Buy) | 457,541 | $0.00 | -- |
| Grant/Award | Common Stock | 313,212 | $0.00 | -- |
Holdings After Transaction:
Performance Restricted Stock Units — 626,424 shares (Direct);
Stock Option (Right to Buy) — 457,541 shares (Direct);
Common Stock — 667,600 shares (Direct)
Footnotes (1)
- Represents shares issuable upon settlement of restricted stock units (RSUs). Each RSU represents the right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments on each anniversary of February 17, 2026, subject to continued service, and may accelerate in certain circumstances (including specified terminations or a change in control). Each performance-based restricted stock unit (PSU) represents the right to receive, upon vesting, up to 200% of the target number of shares of common stock of the issuer. The number of shares issuable upon vesting is based on performance against pre-established financial metrics and relative total shareholder return (TSR) over a three-year performance period ending December 31, 2028. Subject to certification of performance results, any earned PSUs vest following the performance period. The shares subject to the option vest in four equal annual installments on each anniversary of February 17, 2026, subject to continued service, and may accelerate in certain circumstances (including specified terminations or a change in control).
FAQ
What equity awards did David Moatazedi receive from Evolus (EOLS)?
David Moatazedi received performance-based restricted stock units, time-based restricted stock units, and stock options. The grants include 626,424 performance units, 313,212 RSUs, and 457,541 stock options, all awarded at a price of $0.00 per unit or option.
How do the performance-based restricted stock units for EOLS vest?
Each performance-based restricted stock unit can deliver up to 200% of a target share amount. Vesting depends on performance against pre-established financial metrics and relative total shareholder return over a three-year period ending December 31, 2028, subject to certification of results.
When do David Moatazedi’s restricted stock units in Evolus vest?
The restricted stock units vest in four equal annual installments. Vesting occurs on each anniversary of February 17, 2026, and is contingent on continued service, with potential acceleration in certain circumstances such as specified terminations or a change in control.
What is the vesting schedule for David Moatazedi’s Evolus stock options?
The stock options vest in four equal annual installments. Each installment vests on the anniversary of February 17, 2026, as long as service continues, and the vesting may accelerate under certain conditions, including specified terminations or a change in control.
What performance period applies to the Evolus performance-based awards?
The performance period for the performance-based restricted stock units ends on December 31, 2028. Vesting depends on performance against pre-set financial metrics and relative total shareholder return, with any earned units vesting after performance is certified.
Does David Moatazedi pay anything for these Evolus equity grants?
The reported transaction price per share for the awards is $0.00. This indicates the performance units, restricted stock units, and stock options were granted as compensation rather than purchased in an open-market cash transaction.